AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.51
+7.93%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$11.61
From 52W high−45.30%
Volume436064.00
Market cap$670.85M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 20, 2026
Open
$11.61
From 52W high
−45.30%
Volume
436064.00
Market cap
$670.85M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
35.0
MomentumView details →
1D Return
+7.93%
YTD Return
−31.44%
SummaryUpdated Jun 1, 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a clinical-stage precision medicine company founded in 2011 and headquartered in Rockville, Maryland. Originally incorporated as Cerecor Inc., the company rebranded to Avalo Therapeutics in August 2021 to better reflect its focus on developing targeted therapeutics. The company went public in October 2015 and has since evolved into a biotechnology firm specializing in treatments for immunology, immuno-oncology, and rare genetic diseases where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Avalo Therapeutics, Inc. reported that its phase 3 FURVENT trial of furmonertinib did not meet its primary progression-free-survival endpoint in previously untreated patients with EGFR exon 20 insertion non-small-cell lung cancer.14d agoAvalo Therapeutics announced it will present late-breaker oral and poster data at the EADV Congress 2026 in Vienna, Austria, from September 30 to October 3, 2026.27d ago